Preparation method of N- phenyl-2-aminopyrimidine compound and its application
The invention relates to a new N- phenyl-2-aminopyrimidine compound and a medicine composition containing the compound; the N- phenyl-2-aminopyrimidine compound is applied to treat related disease or symptoms of epidermal growth factor receptor (EGFR), such as treat or improve abnormal cell proliferative disease like cancer.
-
Paragraph 0171; 0175; 0176; 0177
(2017/04/28)
PRODUCTION METHOD OF OPTICALLY ACTIVE SECONDARY ALCOHOL
PROBLEM TO BE SOLVED: To provide a chemical catalytic method allowing efficient production of a corresponding optically active secondary alcohol from an aromatic ketone having a substituent at each of two β-positions in an aromatic ring to the carbonyl site, so that both enantiomers can be separately made. SOLUTION: A production method of optically active secondary alcohol is characterized by reacting a ketone compound such as acetophenone derivatives with hydrogen in the presence of a ruthenium complex catalyst having an optically active diphosphine ligand. COPYRIGHT: (C)2015,JPO&INPIT
-
Paragraph 0127; 0129
(2016/11/14)
Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists
A series of orexin receptor antagonists was synthesized based on a substituted piperidine scaffold. Through traditional medicinal chemistry structure-activity relationships (SAR), installation of various groups at the 3-6-positions of the piperidine led to modest enhancement in receptor selectivity. Compounds were profiled in vivo for plasma and brain levels in order to identify candidates suitable for efficacy in a model of drug addiction.
Jiang, Rong,Song, Xinyi,Bali, Purva,Smith, Anthony,Bayona, Claudia Ruiz,Lin, Li,Cameron, Michael D.,McDonald, Patricia H.,Kenny, Paul J.,Kamenecka, Theodore M.
scheme or table
p. 3890 - 3894
(2012/07/13)
TACHYKININ RECEPTOR ANTAGONISTS
The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.
-
Page 28
(2010/02/10)
More Articles about upstream products of 153936-26-6